Helus’ DMT psychedelic touts antidepressant potential in Phase IIa study

by
Pharma companies are increasingly exploring the potential of psychedelics to treat mental health conditions like depression. Image credit: Saklarboy via ShutterStock.com.

Helus Pharma’s psychedelic compound, SPL026, has demonstrated its potential to treat major depressive disorder (MDD) in a mid-stage study.

During a Phase IIa trial (NCT04673383), 34 patients with…

Source link

Related posts:

  1. Page Unavailable – ABC News
  2. HMP is nothing to panic with the virus, not the risk of epidemics –
  3. Kidney Disease Prevention: Awareness is Key
  4. Orthopedic Surgery | Specialized Hospital Services

Leave a Comment